About
Specializing in Lipid-based Nano/micro Particle Medicines
LipoVation’s core technology was conceptualized by Prof. Yehezkel Barenholz, a world-renowned scientist and the inventor of Doxil, the first FDA-approved liposomal chemotherapy drug, widely used in the treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma.
Identity
| Name | Lipovation |
|---|---|
| Slug | lipovation |
| Type / kind | startup |
| Crunchbase ID | lipovation |
| Source _id | dcXh59monCekrZmVXVAsKsbnPamc9wPYVFIPbGXspuZMPr7eQ1jQeS |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Revium Rx on Feb 2025 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Herzliya |
| HQ address | Ha-Menofim St 10, Herzliya, 4672561, Israel |
Web & social
| https://www.linkedin.com/company/3738990 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}